ConductScience.org, home

Paper36757706

Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.

Bornhäuser M and 28 others. JAMA Oncol, 2023. Cited by 43 papers, by iCite.

Cite this record

ConductScience Library. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial. Papers, record 36757706. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36757706

Download JSON
Disease
acute myeloid leukemia587 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
PubMed
Journal
JAMA Oncol
PubMed
Year
2023
PubMed
Publication types
Randomized Controlled Trial, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
43
iCite
Relative citation ratio, by iCite
3.72
iCite
Revised in PubMed
2024-02-10
PubMed

Authors29

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bornhäuser MMartin
2Schliemann CChristoph
3Schetelig JJohannes
4Röllig CChristoph
5Kramer MMichael
6Glass BBertram
7Platzbecker UUwe
8Burchert AAndreas
9Hänel MMathias
10Müller LPLutz P
11Klein SStefan
12Bug GGesine
13Beelen DDietrich
14Rösler WWolf
15Schäfer-Eckart KKerstin
16Schmid CChristoph
17Jost EEdgar
18Lenz GGeorg
19Tischer JJohanna
20Spiekermann KKarsten

Source PubMed

See all 29 authorsDownload CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hematopoietic Stem Cell TransplantationMajor topic
Leukemia, Myeloid, AcuteMajor topic
Humans
Male
Middle Aged
Adolescent
Young Adult
Adult
Female
Consolidation Chemotherapy
Quality of Life
Transplantation, Homologous
Remission Induction
Recurrence

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01246752Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CRDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Cited by37

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 43 citations.

PMIDTitleJournalYearIn PapersSource
42886311Synthetic Notch CD123 and CLL1 chimeric antigen receptor T-cells (CAR-T) target acute myeloid leukemia and reduce off-tumor effects associated with CLL1 CAR-T cells.Mol Biomed2026https://conductscience.org/library/papers/42886311PubMed
42821026FLT3-Mutated AML: Transplanting with Precision in the Targeted Era.Curr Hematol Malig Rep2026https://conductscience.org/library/papers/42821026PubMed
42812306
Allogeneic hematopoietic stem cell transplantation is associated with improved survival compared with chemotherapy in patients with acute myeloid leukemia harboring favorable-risk genetic features at initial diagnosis: a single-center retrospective study.
Front Immunol2026https://conductscience.org/library/papers/42812306PubMed
42640163Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.NEJM Evid2026https://conductscience.org/library/papers/42640163PubMed
42471330Newly diagnosed acute myeloid leukemia in Fit patients: 2026 treatment algorithms.Blood Cancer J2026https://conductscience.org/library/papers/42471330PubMed
42410464Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative study.Exp Hematol Oncol2026https://conductscience.org/library/papers/42410464PubMed
42346269Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions.Curr Oncol2026https://conductscience.org/library/papers/42346269PubMed
42271520Circadian rhythm-guided cellular therapy in hematologic malignancies: mechanisms, clinical evidence, and optimization strategies.Biomark Res2026https://conductscience.org/library/papers/42271520PubMed
42007253Artificial intelligence-based prognostic models in acute myeloid leukemia: systematic review and meta-analysis.Blood Neoplasia2026https://conductscience.org/library/papers/42007253PubMed
41914434Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm.Cancer2026https://conductscience.org/library/papers/41914434PubMed
41686261
Short-course high-dose cytarabine consolidation therapy before allogeneic hematopoietic stem cell transplantation improves 2-year relapse-free survival but not overall survival in patients with acute myeloid leukemia: a single-center retrospective study.
Ann Hematol2026https://conductscience.org/library/papers/41686261PubMed
41596709Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine Plus Pioglitazone and All-Trans Retinoic Acid.Int J Mol Sci2026https://conductscience.org/library/papers/41596709PubMed
41509995Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022.Blood Neoplasia2026https://conductscience.org/library/papers/41509995PubMed
41274886Impact of expanding allogeneic stem cell transplantation on survival in acute myeloid leukemia: a population-based study.Blood Cancer J2025https://conductscience.org/library/papers/41274886PubMed
41139710Current scenario of allogeneic hematopoietic stem cell transplantation in adult patients with relapsed/refractory acute myeloid leukemia: a narrative review.Ann Hematol2025https://conductscience.org/library/papers/41139710PubMed
41131586High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort.Biomark Res2025https://conductscience.org/library/papers/41131586PubMed
40720773Cost-effectiveness of upfront vs delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML.Blood Adv2025https://conductscience.org/library/papers/40720773PubMed
40668660Older matched sibling donor vs young haploidentical donor for older patients with acute myeloid leukemia.Blood Adv2025https://conductscience.org/library/papers/40668660PubMed
40584630Identification of an Ara-C resistance-related gene risk score and the role of S100A4 in AML via NR6A1-dependent activation and p53 regulation.Front Pharmacol2025https://conductscience.org/library/papers/40584630PubMed
40534491
TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Haematologica2025https://conductscience.org/library/papers/40534491PubMed

See all 37 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CEBPA1050PubTator's text mininghttps://conductscience.org/library/genes/1050NCBI Gene
NPM14869PubTator's text mininghttps://conductscience.org/library/genes/4869NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
CYTARABINECHEMBL803Derived from the trial1https://conductscience.org/library/drugs/CHEMBL803

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36757706

GET https://conductscience.org/api/papers/v1/36757706/authors?page=2